An industry association survey has found cases of overseas pharmaceutical companies opting not to launch new drugs in Japan. The trend is believed to be influenced by the implementation of U.S. policies to cut drug prices.
An industry association survey has revealed that some overseas pharmaceutical companies are opting not to launch new drugs in Japan. The survey suggests that the move is driven by U.S. policies to lower prices, taking into account countries such as Japan where drug prices are low.
The survey points to a trend among overseas companies of reconsidering new drug sales in the Japanese market, raising concerns that it could affect the supply of medicines and the options available to patients in Japan.
The article does not identify specific companies or new drugs, but indicates that the decisions are being made under the influence of pricing policies. Further findings from the industry association and the responses of individual companies will be closely watched.
The trend is linked to changes in pharmaceutical price negotiations and market strategies, and could also affect Japan’s drug-pricing system and approval process.